Radioiodine (I-131) is a non-surgical method to treat an overactive thyroid gland (it does not affect the parathyroid glands embedded within the thyroid)
Radioiodine therapy for an overactive thyroid (hyperthyroidism) has recently been endorsed by NICE – as ‘the most effective treatment for the condition (curing 90 % of cases), is a safe treatment and results in improved cardiovascular outcomes for patients with hyperthyroidism’. Click the links below for recent news articles
We have similar experience over the past many years of radioiodine therapy and pleased to see this recognition. Linked below is the published abstract from our experience which emphasises the same with a comparison of lower doses (by an endocrinologist) Vs higher doses (oncologist) with similar outcomes.
Radioiodine is a safe, effective and reliable (but often overlooked) alternative to anti-thyroid drugs and surgery. It is done a single dose (recurrences are rare and can be re-treated) by a capsule or liquid form. Radioiodine is a slow-acting (over a period of 6 weeks to 3 months), non-invasive and painless treatment option (compared to surgery) which is intended to prevent future relapses. (The main outcome is curative but can result in an underactive thyroid). There will be some contact precautions (usually 2 to 3 weeks) and other information the doctor will discuss prior to prescribing radioiodine.